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Abstract
Background: All antipsychotics work via dopamine D2 receptors (D2Rs), suggesting a critical role for D2Rs in
psychosis; however, there is little evidence for a change in receptor number or pharmacological nature of D2Rs.
Recent data suggest that D2Rs form dimers in-vitro and in-vivo, and we hypothesized that schizophrenia, as well as
preclinical models of schizophrenia, would demonstrate altered dimerization of D2Rs, even though the overall
number of D2Rs was unaltered.
Methods: We measured the expression of D2Rs dimers and monomers in patients with schizophrenia using
Western blots, and then in striatal tissue from rats exhibiting the amphetamine-induced sensitized state (AISS). We
further examined the interaction between D2Rs and the dopamine transporter (DAT) by co-immunoprecipitation,
and measured the expression of dopamine D2High receptors with ligand binding assays in rat striatum slices with
or without acute amphetamine pre-treatment.
Results: We observed significantly enhanced expression of D2Rs dimers (277.7 ± 33.6%) and decreased expression
of D2Rs monomers in post-mortem striatal tissue of schizophrenia patients. We found that amphetamine facilitated
D2Rs dimerization in both the striatum of AISS rats and in rat striatal neurons. Furthermore, amphetamine-induced
D2Rs dimerization may be associated with the D2R-DAT protein-protein interaction as an interfering peptide that
disrupts the D2R-DAT coupling, blocked amphetamine-induced up-regulation of D2Rs dimerization.
Conclusions: Given the fact that amphetamine induces psychosis and that the AISS rat is a widely accepted
animal model of psychosis, our data suggest that D2R dimerization may be important in the pathophysiology of
schizophrenia and may be a promising new target for novel antipsychotic drugs.
Background
Schizophrenia is a chronic mental illness, characterized
by episodes of psychotic symptoms that usually emerge
in early adulthood, last a lifetime, and destroy the men-
tal and interpersonal faculties most valued in human
society. The fact that all current antipsychotic drugs
exert their effect through the blockade of D2R empha-
sizes the critical role of hyper-dopaminergic neurotrans-
mission through D2R signaling in the pathophysiology
of schizophrenia [1]. Yet, studies are conflicting about
the role of D2R in the illness. While postmortem studies
have demonstrated an increase in the overall number of
D2R, this is confounded by the fact that this increase
could be a compensatory response to D2R blockade
rather than a diagnostic feature of schizophrenia [2]. On
the other hand, PET imaging studies show unequivocal
support for a change in D2R [3]. Several recent PET
imaging studies show a well-replicated increase in dopa-
mine release in patients with schizophrenia, and even
during the prodromal phase [4]. Thus, it remains
unclear what, if any, the direct role D2R play in the
pathophysiology of schizophrenia.
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Most previous studies have measured D2R using
receptor radioactive ligand binding assay, PET imaging
or Western blot analysis. These techniques provide a
good index of overall binding sites, but do not provide
any insight into molecular aspects of receptor functions,
including their potential configurations with other
receptors. Several GPCRs exist in homo- or hetero-
dimers to allow multiple signal integrations [5]. A num-
ber of studies have focused on the role of dimerization
in regulating the function of GPCRs [5]. Indeed, dimeri-
zation of GPCRs may alter pharmacological properties
and signaling transduction, leading to significant effects
on cellular physiology as well as disease pathologies. For
example, agonist occupancy of one of the two ligand
binding site of the b2-adrenoceptor dimers is sufficient
to cause internalization of the dimers. However, both
binding sites have to be occupied by the antagonist to
prevent agonist-mediated internalization [6]. Further-
more, receptor hetero-dimerization makes it possible to
modulate one receptor using ligands targeting the other
receptor [7-9]. These unique properties of receptor oli-
gomerization have made them novel targets for the
development of novel drugs [10].
Previous studies indicate that D2R are expressed as
monomers and dimers in cell lines and in mammalian
brain tissue [11-14]. Furthermore, D2R have also been
reported as dimers in a variety of neurological disease
such as Alzheimer’s, Parkinson’s and Huntington’s dis-
ease [15,16]. As a result, interest has focused on the
potential pathophysiological role of D2R dimerization in
disease. Although pharmacological studies have sug-
gested that D2R dimers and monomers have differential
affinity for specific dopamine receptor ligands that may
subsequently affect dopamine release [17,18], the func-
tional role of the D2R dimerization and the molecular
mechanisms involved are not well understood.
Thus, the purpose of this study was to examine the
status of D2R dimers and monomers in schizophrenia.
We started with analysis of postmortem striatal sections
from schizophrenia patients and observed a significant
increase in D2R dimers at the expense of monomers. To
examine if this pathology was observed in preclinical
models of schizophrenia that involve a hyper-dopami-
nergic state, we examined the status of D2R dimers in
rats exhibiting an amphetamine-induced sensitized state
(AISS). A similar increase in D2R dimerization was
observed. To further study the molecular basis for this
effect (and to link the alteration in D2 receptors to the
human observation of alteration in presynaptic dopa-
mine release) we examined the status of D2R as well as
their link to the dopamine transporter (DAT) in cul-
tured striatal neurons, with or without acute ampheta-
mine (AMPH) exposure.
Materials and methods
Human postmortem brain tissue
Formalin-fixed paraffin-embedded human postmortem
striatum sections (10 μm-thick on glass slides) were
donated by the Stanley Foundation Neuropathology
Consortium [19]. Subjects were divided into four
groups, including bipolar (BD), major depressive disor-
der (MDD), schizophrenia (SZ), and non-neurological/
non-psychiatric controls (n = 15 per group). Subjects
were matched for age, gender, postmortem interval
(PMI), pH, and mRNA quality. Demographic and medi-
cal information such as drug abuse history and psycho-
tropic treatments were provided by the Stanley
Foundation Neuropathology Consortium. Diagnoses
were retrospectively established by two senior psychia-
trists using DSM-IV criteria. All experiments were per-
formed blinded to the diagnosis of each subject.
Animals
Adult male Sprague-Dawley rats weighing 250-275 g
were procured from Charles River Laboratories, Mon-
treal, Canada. Animals were maintained on a 12-h light/
dark cycle and housed two per cage with continuous
access to food and water. The animals were allowed to
acclimatize to the vivarium for a minimum of 5 days
before being used for experimentation. All experimental
protocols were approved by the CAMH animal care
committee.
Chronic haloperidol treatment
Chronic haloperidol treatment was performed as pre-
viously described [20]. Briefly, groups of 12 rats each
were randomly assigned to receive one of the following
treatments: 0.25 mg/kg/day of haloperidol (McNeil
Pharmaceuticals, Spring House, PA) or vehicle via Alzet
osmotic mini-pumps (Alzet model 2ML4, Durect Cor-
poration, Cupertino, CA) for a total of 2 weeks, to
achieve continuous clinical occupancy.
Amphetamine-induced sensitized state
Amphetamine (Tocris Bioscience, Ellisville, MS) were
given three times a week (Monday, Wednesday and Fri-
day) for 5 weeks via intraperitoneal injection (IP). Dur-
ing week 1, amphetamine treated animals received a
dose of 1 mg/kg (from salt); with the dose increasing by
1 mg/kg each week so that the dose in the final week
was 5 mg/kg. Control animals received saline. All injec-
tions were administered in a 1 ml/kg volume.
Acute striatal slices
Acute striatal slices (350 μm-thick) were prepared from
Sprague-Dawley rats using a McIlwain tissue chopper
(Mickle Laboratory Engineering, Gomshall, United
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Kingdom). Rat striata were dissected out and left for
5 min in ice-cold artificial cerebrospinal fluid (aCSF)
containing 126 mM NaCl, 2.5 mM KCl, 1 mM MgCl2,
1 mM CaCl2, 1.25 mM KH2PO4, 26 mM NaHCO3 and
20 mM glucose, that was bubbled continuously with
carbogen (95% O2/5% CO2) to adjust the pH to 7.4.
Freshly cut slices were placed in an incubating chamber
with carbogenated aCSF and recovered from stress at
37°C for 1 hour. Slices were then treated with 10 μM
AMPH for 30 min. Slices were then harvested for Wes-
tern blot analysis.
Primary cultured striatal neurons
Primary cultures from striatum were prepared from fetal
Wistar rats (embryonic day 17-19) on culture dishes as
previously described [21]. The cultures were used for
experiments 12-15 days after plating.
HEK293T cell culture conditions and transfection
HEK293T cells were cultured in a-MEM (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine
serum (Invitrogen) and maintained in incubators at 37°C,
5% CO2. One day before transfection, cells were split
onto poly-D-lysine coated plates. For lipofectamine2000
transfections, DAT: D2R cDNA ratio of 1:5 to maximize
coexpression. Cells were utilized 2 days post transfection.
Co-immunoprecipitation
Co-immunoprecipitation was performed as previously
described [21,22]. Briefly, solubilized rat striatal extracts
(500~700 μg) were incubated in RIPA buffer with pri-
mary antibody anti-D2 (Millipore, Billerica, MA) or rab-
bit IgG (1~2 μg, Sigma-Aldrich, St. Louis, MO) for 4 h
at 4°C, followed by the addition of 20 μl of protein A/G
agarose (Santa Cruz, Santa Cruz, CA) for 12 h. Pellets
were washed, boiled for 5 min in SDS sample buffer and
subjected to SDS-PAGE. 20~50 μg of tissue extracted
protein was used as a positive control in each experi-
ment. Anti-DAT (Santa Cruz) was applied as the immu-
noblotting antibody in the following western blot
analyses.
Western blot
Western blot analyses were performed as previously
described [21,22]. Briefly, formalin-fixed paraffin-
embedded frozen human postmortem striatal sections
from the Stanley Consortium (scraped off the glass
slides), rat striatum, HEK293T cells and cultured rat
striatal neurons (~2 × 107) were homogenized in RIPA
buffer (50 mM Tris-Cl, pH 7.6, 150 mM NaCl, 2 mM
EDTA, 1 mM PMSF plus 1% Igepal CA-630, 0.5%
sodium deoxycholate, 1% Triton X-100) with a protease
inhibitor cocktail (Sigma-Aldrich), and centrifuged at 4°
C at 13,000 rpm for 10 min. Supernatant was extracted
and protein concentrations were measured (Bio-Rad,
Hercules, CA). Protein samples (50 μg) were boiled for
5 min in SDS sample buffer, and subjected to SDS-
PAGE. Blots were blocked with 5% non-fat dried milk
dissolved in TBST buffer (10 mM Tris, 150 mM NaCl,
and 0.1% Tween 20) for 1 h at room temperature,
washed three times with TBST buffer, incubated with
the appropriate primary antibody [anti-D2 (polyclonal)
or anti-a-tubulin (monoclonal, Sigma-Aldrich) diluted
in 5% milk in TBST] overnight at 4°C. The blots were
washed again with TBST buffer three times and then
incubated with horseradish peroxidase-conjugated sec-
ondary antibody (diluted in 5% milk in TBST; Sigma-
Aldrich) for 1.5 h at room temperate. The proteins were
visualized with enhanced chemiluminescence reagents
(GE Healthcare, Piscataway, NJ).
Inhibition of [3H]-domperidone binding to D2R
The striatal tissue was homogenised (final concentration
of 4 mg/ml) in a buffer containing 50 mM Tris-HCl
(pH 7.4 at 20°C), 1 mM EDTA, 5 mM KCl, 1.5 mM
CaCl2, 4 mM MgCl2 and 120 mM NaCl, using a Teflon-
glass homogeniser with the piston rotating at 500 RPM
and 10 up-and-down strokes of the glass container.
Similar results were obtained with either washed or
non-washed homogenates. Although it is known that
approximately half the D2R can be lost upon washing
the tissue [23], the homogenates were washed by centri-
fuging the homogenate at 10,000 × g for 10 min and
discarding the supernatant; this procedure was repeated
two more times. The final pellet was used.
The D2R in the striatal tissue were measured with
[3H]-domperidone (2 nM final concentration; custom
synthesized as [phenyl-3H(N)]-domperidone; 41.4 Ci/
mmol; Moravek Radiochemicals Inc., Brea, CA) [24].
Each incubation tube (12 × 75 mm, glass) received, in the
following order, 0.5 ml buffer, containing a range of
dopamine concentrations, with or without a final concen-
tration of 10 μM S-sulpiride (to define nonspecific D2R
binding), 0.25 ml [3H]domperidone (generally 1.8 nM as
the final concentration in the incubation tube), and 0.25
ml of tissue homogenate. Each concentration of dopa-
mine was tested in duplicate. The tubes, containing a
total volume of 1 ml, were incubated for 2 h at room
temperature (20°C), after which the incubates were fil-
tered, using a 12-well cell harvester (Titertek, Skatron,
Lier, Norway) and buffer-presoaked glass fiber filter mats
(Whatman GF/C). After filtering the incubates, the filter
mat was rinsed with buffer for 15 s (7.5 ml buffer), and
the filters were processed as detailed above. The specific
binding of [3H]-domperidone was defined as total bind-
ing minus that in the presence of 10 μM S-sulpiride.
Independent saturation of D2R, using a range of
[3H]-domperidone concentrations, revealed a [3H]-
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domperidone dissociation constant (Kd) of 0.48 ±
0.08 nM (n = 6) for the rat homogenized striata.
TAT peptides pre-treatment
The acute rat striatal slices were pre-treated with TAT-
fused peptides (30 min, 10 μM) before amphetamine
treatment. TAT-fused peptides were synthesized by
GeneScript. Peptides are rendered cell permeant by fus-
ing to the cell membrane transduction domain of the
human immunodeficiency virus type 1 TAT protein
(YGRKKRRQRRR), as previously described [25].
Densitometry and statistical analysis
To quantify the bands obtained via Western blot analy-
sis, we applied ImageJ software based analysis (http://
rsb.info.nih.gov/ij/). The area under curve (AUC) of the
specific signal was corrected for the AUC of the loading
control (e.g. a-tubulin). All values are provided as
means ± SEM. For comparisons between two groups, t-
test (two-tailed) was performed. For comparisons of
more than two groups, one-way ANOVA followed by
SNK post-hoc analysis was performed. Unless otherwise
noted, significance level was set at 0.05.
Results
Enhanced expression of D2R dimers in postmortem
striatal sections from schizophrenia patients
As an initial step to investigate whether the expression
pattern of D2R might be altered in schizophrenia, we
carried out Western blot analysis with all 60 formalin-
fixed paraffin-embedded human postmortem striatal
sections from the Stanley Foundation, including 15 sam-
ples from each of four groups: control, bipolar disorder
(BD), major depressive disorder (MDD) and schizophre-
nia (SZ). A polyclonal anti-D2 antibody that can specifi-
cally recognize both D2R dimers and monomers was
used to examine the D2R expression in Western blot
analysis (Additional File 1). As shown in Figure 1A-B,
the expression level of D2R dimers exhibited a signifi-
cant increase (277.7 ± 33.6%) in the postmortem striatal
sections of schizophrenia patients (n = 15, p < 0.001),
whereas the expression of D2R monomers showed a
substantial decrease (69.3 ± 7.3%, Figure 1A, C). These
data suggest D2R dimerization may contribute to the
pathophysiology of schizophrenia.
We are aware of the fact that most of the schizophrenia
patient samples (13/15) we examined were exposed to
antipsychotic treatment ante-mortem. Thus, to rule out
the possibility that the observed enhancement of D2R
dimerization in the human postmortem schizophrenia
striatal sections is the consequence of antipsychotic
treatment, we tested the expression of D2R dimerization
in striatal brain tissue of rats chronically treated with
haloperidol. As shown in Figure 1D-E, haloperidol
treatment failed to alter the degree of D2R dimerization.
Furthermore, AMPH-induced D2R dimerization was not
affected by the haloperidol treatment in rat striatal slices
(Figure 1F-G). Taken together, these data suggest that
Figure 1 D2R expression in postmortem striatal tissue of
schizophrenia patients. A. Representative Western blot analysis of
the expression levels of D2R dimmers and monomers in human
postmortem striatal sections of control, bipolar, depression and
schizophrenia groups. a-tubulin was used as a loading control. B-C
Bar graphs summarizing the Western blot data of D2R dimers (B)
and monomers (C). *, ***Significantly different from control group (p
< 0.05, p < 0.001; n = 15). Data were analyzed by One-way ANOVA,
followed by SNK post-hoc test. D-E, Chronic haloperidol treatment
caused no significant changes in the expression of D2R dimers and
monomers in rat striatal tissue compare to control group (n = 12).
Data were analyzed by t-test. F-G, Western blot analysis of the
expression levels of D2R dimers (F) and monomers (G) in rat striatal
slices treated with AMPH (30 min, 10 μM), in the presence or
absence of haloperidol (30 min, 10 μM). *, **Significantly different
from control group (p < 0.05, p < 0.01; n = 3). Data were analyzed
by One-way ANOVA, followed by SNK post-hoc test.
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the observed increment of D2R dimers may not be
caused by the antipsychotic treatment.
D2R dimerization was up-regulated in the striatal
tissue of AISS rats
Due to the similarity between schizophrenia and amphe-
tamine psychosis [26-28], the amphetamine-induced
sensitized state (AISS) has been widely used as an ani-
mal model of schizophrenia. Thus, we investigated
whether the expression pattern of D2R is also altered in
the striatum of AISS rats. As shown in Figure 2A-B, the
expression of D2R dimer was significantly increased
(415.3 ± 56.6%) in the AISS group compared to con-
trols; the D2R monomer was significantly reduced in the
AISS group compare to the control group (19.6 ± 5.0%,
Figure 2A, C). These data suggest that chronic ampheta-
mine exposure, which leads to a sensitized state and
models many aspects of the clinical illness, also displays
the same alteration that is seen in the postmortem stria-
tal sections of schizophrenia patients.
D2R dimerization may be associated with D2high
receptors
Previous studies have shown that in many animal models
for psychosis, including the AISS, the proportion of D2R
in the high-affinity state is elevated [29]. However, the
molecular basis that renders D2R super-sensitive to dopa-
mine remains unclear. As both D2R dimers and D2high
receptors are enhanced in the AISS animal model, we
speculate that D2R dimerization may correlate with the
D2R high-affinity state. We tested our hypothesis in rat
striatal slices treated with amphetamine. Thus, rat striatal
slices were treated with amphetamine and divided ran-
domly into two groups: one for D2R dimer measurement
and the other for D2high receptors measurement. As
shown in Figure 3A-B, acute amphetamine treatment sig-
nificantly enhanced the expression of D2R dimers (295.0 ±
75.4%), while the D2R monomer expression was signifi-
cantly decreased (39.9 ± 19.5%). Similarly, acute treatment
with amphetamine increased the proportion of high-affi-
nity D2R from 17 ± 1.4% to 38.8 ± 3.9% (Figure 3C),
examples of which are shown in Figure 3D. These data
suggest that D2R dimers may be associated with the
super-sensitivity of D2R to dopamine.
Amphetamine facilitates D2R dimerization in
primary culture of rat striatal neurons
In order to identify the factors involving in the process
of amphetamine-induced D2R dimerization, we then
tested the amphetamine effect on D2R dimerization in a
simplified experimental condition. Primary culture of rat
striatal neurons was treated with 10 μM amphetamine
for 30 min at 37°C. Consistent with the result from
AISS rats, acute amphetamine treatment facilitated D2R
dimerization (537.5 ± 37.5%, Figure 4A), whereas the
expression of D2R monomers was significantly
decreased (14.9 ± 1.4%) in amphetamine-treated groups
(Figure 4B). Since amphetamine is able to enhance
synaptic dopamine, we then tested whether the observed
amphetamine-induced up-regulation of D2R dimeriza-
tion is a consequence of activation of D2R. Both quin-
pirole (10 μM, 30 min), a specific D2R agonist, and
dopamine (10 μM, 30 min) failed to up-regulate D2R
dimerization (Figure 4C-D); indicating that D2R activa-
tion alone is not sufficient to account for the ampheta-
mine-induced up-regulation of D2R dimerization. More
interestingly, amphetamine stimulation also failed to up-
regulate D2R dimerization in HEK-293T cells trans-
fected only with D2R, suggesting the involvement of
additional proteins that exist in striatal neurons but not
in transfected cells (Figure 4E-F).
D2R-DAT protein-protein interaction is involved in
amphetamine-induced D2R dimerization
Previous studies have shown that amphetamine increases
dopamine concentration in the synaptic cleft by reversing
DAT-mediated dopamine uptake. Based on the fact that
both D2R activation alone and amphetamine stimulation
in HEK-293T cells expressing D2R failed to up-regulate
D2R dimerization, we speculate that DAT may be one of
Figure 2 Amphetamine induces D2R dimerization in AISS rat
striatum. A, Western blot analysis of the expression levels of D2R
dimers and monomers in striatal extracts of control and AISS rats. a-
tubulin was used as a loading control. B-C, Bar graphs summarizing
the western blot data. *, **Significantly different from control group
(p < 0.05, p < 0.01; n = 5). Data were analyzed by t-test.
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the additional proteins that play a role in this process. To
explore whether the existence of DAT is necessary for
D2R dimerization, we examined the AMPH-induced D2R
dimerization in HEK293T cells co-expressing D2R and
DAT, and in HEK293T cells co-expressing D2R and
pcDNA3, a mammalian expression vector in which DAT
is subcloned. As shown in Figure5A-B, AMPH failed to
up-regulate D2R dimerization in the absence of DAT.
We have previously reported that the D2R forms a pro-
tein complex with DAT through direct protein-protein
interactions [30]. Thus, if amphetamine induces up-
regulation of D2R dimerization through a D2R-DAT
interaction, disruption of the D2R-DAT interaction with
Figure 3 Amphetamine facilitates D2R dimerization and the
expression of high-affinity D2 receptors (D2high) in rat striatal
brain slices. A-B, Western blot analysis of the expression levels of D2R
dimers (A) and monomers (B) in rat striatal slices treated with or
without AMPH (30 min, 10 μM). *Significantly different from control
group (p < 0.05; n = 3). Data were analyzed by t-test. C, Bar graph
summarizing the binding of [3H]domperidone in rat striatal slices
treated with or without AMPH (30 min, 10 μM). ***Significantly
different from control group (p < 0.001; n = 7 in control group and n
= 6 in AMPH group). D, Graphs representing three samples out of six
experiments. The competition between dopamine and [3H]
domperidone showed a biphasic pattern. In control striata, low
concentrations of dopamine (generally between 10 and 5,000 nM)
inhibited the binding of [3H]domperidone by an average of 17 ± 1.4%.
Higher concentrations of dopamine further reduced the binding of
[3H]domperidone in a distinctly separate phase. There was a clear
plateau between the high-affinity phase (i.e., at low concentrations of
dopamine) and the low-affinity phase (i.e., at high concentrations of
dopamine). The treatment with amphetamine increased the
proportion of high-affinity D2 receptors to 38.8% ± 3.9%.
Figure 4 Amphetamine facilitates D2R dimerization in rat striatal
neurons. A-B, Western blot analysis of the expression levels of D2R
dimers (A) and monomers (B) in primary cultures of rat striatal
neurons treated with or without AMPH (30 min, 10 μM).
***Significantly different from control group (p < 0.001; n = 5). Data
were analyzed by t-test. C-D, Western blot analysis of the expression
levels of D2R dimers (C) and monomers (D) in primary cultures of rat
striatal neurons treated with quinpirole (10 μM), dopamine (10 μM) or
AMPH (10 μM). *, **Significantly different from control group (p < 0.05,
p < 0.01; n = 5). Data were analyzed by One-way ANOVA, followed by
SNK post-hoc test. E-F, Western blot analysis of the expression levels of
D2R dimers (E) and monomers (F) in HEK-293T cells transfected with
D2R in the presence or absence of AMPH (30 min, 10 μM; n = 3).
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the interfering peptide TAT-DATNT1-1 encoding
sequence of the interaction site of D2R-DAT within
DAT [previously shown to disrupt D2R-DAT coupling
[30]] should block the amphetamine-induced up-regula-
tion of D2R dimerization. Consistent with our hypoth-
esis, pre-treatment with TAT-DATNT1-1 peptide (30 min,
10 μM) blocked amphetamine-induced enhancement of
D2R dimer formation (Figure 5C-E), while TAT-only and
TAT-DATNT1-2 peptide (encodes scrambled sequence of
TAT-DATNT1-1 peptide) showed no effect. The ability of
TAT-DATNT1-1 peptide to disrupt D2R-DAT interac-
tions was confirmed in a parallel co-immunoprecipitation
experiment (data not shown). Taken together, these
results suggest that D2R-DAT interaction may be neces-
sary for the amphetamine-induced up-regulation of D2R
dimerization and that this interaction may also contri-
bute to the pathophysiology of schizophrenia.
Discussion
In summary, we have identified a potential role for D2R
dimerization in the pathology of schizophrenia. This
conclusion is based on our observations of enhanced
expression of D2R dimers in postmortem human striatal
sections of schizophrenia patients and in the striatum of
an animal model of schizophrenia (AISS), as well as the
acute amphetamine-induced up-regulation of D2R
dimerization. Additionally, we provided evidence that
the physical coupling between D2R and DAT may be
necessary for this amphetamine-induced up-regulation
of D2R dimerization.
It has been long recognized that D2R exists in both
monomers and dimers in brain. However, the mechan-
isms regulating this process as well as the physiological/
pathological roles of dimerization remain unknown. Our
data provide the first direct evidence that both acute
and chronic amphetamine treatments regulate D2R
dimerization. Previous studies have shown that amphe-
tamine enhances synaptic dopamine concentrations by
the blockade and reversal of DAT-mediated dopamine
uptake [31-33]. Thus, an obvious explanation may be
that the enhanced synaptic dopamine over-stimulates
D2R and increases D2R dimerization. However, our
results shown in Figure 4C-D indicate that activation of
D2R is not sufficient to induce D2R dimerization. We
also observed that acute amphetamine treatment failed
to induce D2R dimerization in HEK-293T cells expres-
sing D2R only (Figure 4E-F), suggesting the involvement
of additional proteins/receptors in this process. Given
that synaptic dopamine activates not only D2R but all
dopamine receptor subtypes D1-D5, the observed
amphetamine-induced up-regulation of D2R dimeriza-
tion may also be involved in the activity of other dopa-
mine receptors, such as D1R. Indeed, previous studies
have shown a functional interaction between D1R and
D2R, and the D1R and D2R may form a protein com-
plex [34-36]. In addition to D1R, recent studies have
shown that D2R can also interact with other receptors
or channels, such as D3R [37], Somatostatin sst5 recep-
tor [38], Adenosine A2A receptor [39] and Kir3 K
+ chan-
nel [40]. Several dopamine receptor interacting proteins
(DRIPs) have also been identified to be directly and
indirectly associated with D2R, including protein
4.1N/B/G [41], FilaminA [42], Spinophilin [43], GIPC
[44], CAPS1 [45], ZIP [46], NCS-1 and GRK2 [47].
Future investigations may focus on studying the role of
DRIPs as well as other D2R-interacting receptors in the
AMPH-mediated D2R dimerization.
Figure 5 Alteration of D2R-DAT protein-protein interaction in
AISS rats. A-B,Western blot analysis of the expression levels of D2R
dimers (A) and monomers (B) in HEK-293T cells co-expressing D2R/
pcDNA3 or D2R/DAT in the presence or absence of AMPH (30 min,
10 μM; n = 3). *Significantly different from D2R/DAT control group
(p < 0.05; n = 3). Data were analyzed by t-test. C, Western blot
analysis of the expression levels of D2R dimers and monomers in rat
striatal slices treated with TAT-fused peptides (30 min, 10 μM)
followed by amphetamine exposure (30 min, 10 μM). D-E, Bar
graphs summarizing the western blot data. *Significantly different
from control group (p < 0.05, n = 3). Data were analyzed by One-
way ANOVA, followed by SNK post-hoc test.
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In many animal models of psychosis, the proportion of
D2R in the high-affinity state is elevated 2- to 9-fold in
the striatum of rats known to be supersensitive to dopa-
mine [27,48,49]. Our current finding that amphetamine
induces an increase in the proportion of D2High recep-
tors and an increase in the D2R dimers in rat tissue sug-
gests that dimerization may be closely related to the
dopamine-based hyperactivity elicited by amphetamine.
Previously, we reported that D2R directly interact with
DAT, and the D2R-DAT protein complex formation
enables D2R to up-regulate DAT-mediated dopamine
uptake by recruiting DAT to the plasma membrane [30].
However, the role of D2R-DAT interaction in the regula-
tion of D2R function remains unknown. In the current
study, we provided evidence that disruption of the D2R-
DAT interaction blocks amphetamine-induced up-regu-
lation of D2R dimerization in transfected HEK293T cells,
implicating the potential role of DAT in this process.
However, it is worth noting that the AMPH-induced
increase in D2R dimers seems to have bands that are
more intense than the monomer bands. If the DAT is the
only molecule required for this process, it may appear
surprising that the DAT in such a small fraction of TH-
positive neurons accounts for a large increase in DRD2
dimers in the cultured striatal neurons. Thus, there is a
high probability that other additional molecules may be
involved in D2R dimerization.
We have shown that D2R dimerization is enhanced in
postmortem striatal sections from schizophrenia
patients, and that amphetamine, a psychomotor stimu-
lant that can induce psychosis, up-regulates D2R dimeri-
zation that in turn may be responsible for the noted
dopamine hypersensitivity in schizophrenia. While the
current antipsychotic treatments block dopamine D2
receptors, our data show that they do not alter the level
of D2 dimers by themselves. Information from Stanley
foundation indicated that 13 out of 15 patients in the
schizophrenia group have received antipsychotic treat-
ments and exhibited the increment of D2R dimerization.
However, 12 out of 15 patients in the bipolar group
have also received antipsychotic treatments but did not
display an enhanced D2R dimerization. Therefore, a
treatment focused at reversing the increased D2 dimeri-
zation my be closer to the pathophysiology of schizo-
phrenia and may provide a novel therapeutic target for
development of antipsychotics. Previous studies have
shown that D2R forms dimers through multiple sites
including transmembrane domain 4 [50]. Thus, further
studies should be carried out to identify the exact inter-
acting site(s) that are responsible for D2R dimer forma-
tion and interfering peptide(s) then can be developed
and tested as potential antipsychotic agents in animal
models of schizophrenia.
Additional material
Additional file 1: Specificity of D2R antibody. Western blot analysis of
dopamine receptor D2 dimer and monomer expression in both rat and
human striatal extracts.
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